Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. [electronic resource]
Producer: 19920325Description: 398-405 p. digitalISSN:- 0732-183X
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Blast Crisis -- drug therapy
- Bone Marrow Diseases -- chemically induced
- Cytarabine -- administration & dosage
- Daunorubicin -- administration & dosage
- Granulocyte-Macrophage Colony-Stimulating Factor -- therapeutic use
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukemia, Myeloid, Accelerated Phase -- drug therapy
- Middle Aged
- Prognosis
- Remission Induction
- Survival Analysis
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.